Your search for baricitinib returned 48 results

Methods to prevent and treat COVID-19 in cancer patients have had to evolve alongside the SARS-CoV-2 virus.

Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The approval was based on data from the phase 2/3 BRAVE-AA1 and phase 3 BRAVE-AA2 trials, which included adults with severe alopecia areata.

The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.

Abrocitinib, 200 mg daily, and upadacitinib, 30 mg daily, slightly better than dupilumab, while upadacitinib, 15 mg daily is similar to dupilumab

Reduction in death seen at 28, 60 days for patients receiving invasive mechanical ventilation, extracorporeal membrane oxygenation

Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.

JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19

The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.